Previous 10 | Next 10 |
2023-05-11 17:42:48 ET Equillium press release ( NASDAQ: EQ ): Q1 GAAP EPS of -$0.11 beats by $0.07 . Revenue of $8.9M. Research and development (R&D) expenses for the first quarter of 2023 were $9.3 million, compared with $10.8 million for the same period in 2...
$62.0 million cash balance at the end of Q1 2023 expected to provide operating runway into 2025 Presented Phase 1b EQUATE data in aGVHD highlighting rapid and durable rates of overall clinical response, clinical response associated with improved progression-free survival through one year,...
Quarterly revenue increases 38% sequentially TORONTO, ON / ACCESSWIRE / April 28, 2023 / EQ Inc. (TSXV:EQ) ("EQ Works" or the "Company"), a leader in geospatial data and artificial intelligence driven software, announced its financial results today for the fourth quarter and the year ended D...
Itolizumab in combination with systemic corticosteroids was associated with high rates of overall clinical response Response at Day 29 was associated with improved progression-free survival through 1 year Itolizumab is being evaluated in pivotal Phase 3 EQUATOR study in first-line...
2023-03-23 16:39:21 ET Equillium press release ( NASDAQ: EQ ): Q4 GAAP EPS of $0.08 in-line. Revenue of $15.76M beats by $5.36M . Shares +1.22% . For further details see: Equillium GAAP EPS of $0.08 in-line, revenue of $15.76M beats by $5.36M
$71.0 million cash balance at the end of 2022 expected to provide cash runway into 2025 Acquired Bioniz Therapeutics, including two first-in-class clinical-stage assets, EQ101 and EQ102, and proprietary product discovery platform Initiated Phase 2 clinical study of EQ101 in alopec...
Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company focused on developing novel therapeutics to treat severe autoimmune and inflammatory disorders with high unmet medical need, today announced that it will present at the H.C. Wainwright Autoimmune & Inflammatory Disease Virtu...
TORONTO, ON / ACCESSWIRE / February 22, 2023 / EQ Inc. (TSXV:EQ) ("EQ Works" or the "Company"), a leader in geospatial data and artificial intelligence driven software, is pleased to announce that it has been recognized by the TSX Venture Exchange as one of the top 10 performing technology stock...
Itolizumab was associated with high clinical response rates at Day 15 and 29 Responders were able to taper steroids by 70% at Day 29 and 99% at Day 169 Itolizumab being evaluated in pivotal Phase 3 EQUATOR study in first-line acute graft-versus-host disease ...
Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company focused on developing novel therapeutics to treat severe autoimmune and inflammatory disorders with high unmet medical need, today announced that it will present at the SVB Securities Annual Global Biopharma Conference. Mana...
News, Short Squeeze, Breakout and More Instantly...
Equillium Inc. Company Name:
EQ Stock Symbol:
NASDAQ Market:
Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company focused on developing novel therapeutics to treat severe autoimmune and inflammatory disorders, today announced that it expects to join the Russell Microcap Index at the conclusion of the 2024 Russell annual reconstitution, effe...
A look at the top 10 most actives in the United States SOBR Safe Inc. (SOBR) rose 74.6% to $0.46 on volume of 265,324,361 shares MicroAlgo Inc. (MLGO) rose 669.9% to $12.01 on volume of 183,977,846 shares PROSHARES TRUST (SQQQ) fell 0.7% to $9.86 on volume of 124,114,596 shares Faraday ...
A look at the top 10 most actives in the United States SOBR Safe Inc. (SOBR) rose 115.1% to $0.5667 on volume of 77,631,052 shares MicroAlgo Inc. (MLGO) rose 284.0% to $5.99 on volume of 40,752,997 shares Crown Electrokinetics Corp. (CRKN) fell 13.8% to $0.1016 on volume of 28,247,104 sha...